Dendrite Opens Representative Office/Wins New Business in China; Shanghai Office To Roll Out Palm-Top Solution For Large European Pharmaceutical Company in China.

Business Editors/Health & Medical Writers

MORRISTOWN, N.J.--(BUSINESS WIRE)--Oct. 22, 2001

Dendrite (NASDAQ/NMS: DRTE), the visionary innovator in global pharmaceutical technology, today announced that it has opened a new Representative Office in Shanghai, China, to begin service to that country's growing pharmaceutical industry.

Dendrite's office will offer a broad range of services for both Chinese and international pharmaceutical companies operating in China.

"Pharmaceutical sales forces are growing faster in China than in any other market," said Jean-Paul Modde, Dendrite Vice President, Asia/Pacific. "As a result, the industry is being challenged to make its sales forces as productive as possible. Our new office in Shanghai will help drug companies achieve their growing requirements and ambitious sales goals, offering enormous potential for both them and Dendrite."

Dendrite also announced that it recently signed a new multi-year services contract with the Chinese division of a large European pharmaceutical company. Under the agreement, the company will deploy a palm-top version of Medicheck(TM) for its entire sales force in China.

The new contract adds to Dendrite's existing client base in that country. Two additional companies in China are using Dendrite's Medicheck(TM) solution; the recent contract marks the first deployment of a Dendrite palm-top solution in China.

Medicheck(TM) is a component of Dendrite's Sales Force Effectiveness solution set that has been developed specifically to meet the needs of pharmaceutical sales forces in Asia, Latin America, Eastern Europe, and the Middle East. The system is composed of application and training components that make information access and application easy and actionable for the sales force.

About Dendrite

Dendrite, the visionary innovator in global pharmaceutical technology, helps clients strategically manage customer relationships to increase market share. The company creates unique, analytically driven solutions that enable pharmaceutical companies to influence prescriber behavior, thereby delivering a sustained competitive advantage. More than 80,000 pharmaceutical sales representatives and their managers from over 150 companies and 57 countries use Dendrite products and services. They represent 19 of the top 20 pharmaceutical companies. For more information, visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including: risks associated with and dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy selling cycles, product implementation cycles, customer budget cycles, and timing of revenue recognition; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; retention of key senior managers; and unique characteristics of the consumer packaged goods industry. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.